Trump announces new deals with drugmakers to lower prices for Americans
President Trump announces deal to reduce cost of weight loss drugs
President Trump delivered remarks from the Oval Office Thursday, announcing a deal with pharmaceutical manufacturers Eli Lilly and Novo Nordisk to reduce the cost of certain popular weight loss drugs. The press conference ended abruptly after one of the participants experienced a medical episode.
President Donald Trump announced Friday his administration has reached new agreements with some of the world’s largest drug manufacturers aimed at lowering prescription drug costs for Americans.
Speaking from the Roosevelt Room, Trump revealed nine additional drug manufacturers have agreed to the administration’s most-favored-nation pricing initiative, bringing the total to 14 of the 17 largest leading companies in the world.
The agreement reached with the nine companies also encompasses $150 billion in combined new investment commitments in domestic manufacturing, research and development of pharmaceuticals.
Friday’s announcement ushered in deals with Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi – signifying a successful bargain between the manufacturers and the Trump administration.
FOX NEWS POLL: VOTERS SOUND ALARM ON HEALTHCARE COSTS
In July, Trump penned letters to the leaders of the 17 largest drug manufacturers looking to strike a deal to keep drug costs for those enrolled in the government's Medicaid health program below those of other high-income countries.
U.S. President Donald Trump announces a deal with Pfizer to lower Medicaid drug prices in the Oval Office of the White House on September 30, 2025 in Washington, DC. (Credit: Win McNamee/Getty Images / Getty Images)
Several of the current signees have also agreed to donate active pharmaceutical ingredients to America's Strategic Active pharmaceutical Ingredients Reserve (SAPIR SAPIR) to aid in the country’s disaster response to potential pandemics, natural catastrophes or national security emergencies.
Previously, Pfizer, AstraZeneca and Serrano, Novo Nordisk and Lilly had signed onto deals with the Trump administration to keep drug prices manageable for low-income Americans.
TRUMP'S QUEST TO REDUCE DRUG PRICES IS HEATING UP. BUT WILL HE BE ABLE TO DO IT?
Trump has routinely made prescription drug costs a keystone of his administration’s efforts, often focusing on the disparity between prices in the U.S. and other wealthy countries, with analysts noting Medicaid – which accounts for 10% of the country’s drug spending – already benefits from significant manufacturer discounts, according to Reuters.
Trump also announced the administration’s new website, TrumpRX.gov, is set to launch early next year in an effort to lower prescription drug prices for Americans. A message listed on the site currently reads, "Coming soon. January 2026."